<scp>E3</scp> ubiquitin ligase <scp>MID1</scp> ubiquitinates and degrades <scp>type‐I</scp> interferon receptor 2

Xiangjie Chen, Qian Zhao, Ying Xu, Qiuyu Wu, Renxia Zhang, Qian Du, Ying Miao, Yibo Zuo, Fan Huang, Tengfei Ren,

Immunology · 2022 · 11 citations · 39 references

DOIFull text

Open access

Concepts

Abstract

Type I interferon (IFN-I) is a common biological molecule used for the treatment of viral diseases. However, the clinical antiviral efficacy of IFN-I needs to be greatly improved. In this study, IFN-I receptor 2 (IFNAR2) was revealed to undergo degradation at the protein level in cells treated with IFN-I for long periods of time. Further studies found a physical interaction between the E3 ubiquitin ligase midline-1 (MID1) and IFNAR2. As a consequence, MID1 induced both K48- and K63-linked polyubiquitination of IFNAR2, which promoted IFNAR2 protein degradation in a lysosome-dependent manner. Conversely, knockdown of MID1 largely restricted IFN-I-induced degradation of IFNAR2. Importantly, MID1 regulated the strength of IFN-I signalling and IFN-I-induced antiviral activity. These findings reveal a regulatory mechanism of IFNAR2 ubiquitination and protein stability in IFN-I signalling, which could provide a potential target for improving the antiviral efficacy of IFN-I.

References

39